Organogenesis Holdings Inc.

Equities

ORGO

US68621F1021

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-05-01 pm EDT			5-day change	1st Jan Change
2.51 ^USD	+6.81%		-15.77%	-38.63%

Feb. 29	Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024
Feb. 29	Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	CI

Organogenesis Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023

February 29, 2024 at 04:05 pm EST

Organogenesis Holdings Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported sales was USD 99.65 million compared to USD 115.52 million a year ago. Net loss was USD 0.568 million compared to net income of USD 7.49 million a year ago.

Latest news about Organogenesis Holdings Inc.

Transcript : Organogenesis Holdings Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Organogenesis Holdings Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q4 Revenue $99.7M, vs. Street Est of $109.1M	Feb. 29	MT
Organogenesis Holdings Inc. Provides Earnings Guidance for the First Quarter and for the Year Ending December 31, 2024	Feb. 29	CI
Organogenesis Holdings Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Organogenesis Holdings Insider Sold Shares Worth $940,860, According to a Recent SEC Filing	Jan. 11	MT
BTIG Raises Price Target on Organogenesis Holdings to $6 From $4, Keeps Buy Rating	Dec. 27	MT
Morgan Stanley Adjusts Price Target on Organogenesis to $3.50 From $3, Maintains Equalweight Rating	Nov. 14	MT
Transcript : Organogenesis Holdings Inc., Q3 2023 Earnings Call, Nov 09, 2023	Nov. 09
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q3 Revenue $108.5M, vs. Street Est of $111.4M	Nov. 09	MT
Organogenesis Holdings Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Organogenesis Holdings Inc. Provides Earnings Guidance for the Year Ending December 31, 2023	Nov. 09	CI
Transcript : Organogenesis Holdings Inc. Presents at Morgan Stanley 21st Annual Global Healthcare Conference 2023, Sep-11-2023 08:00 AM	23-09-11
Stocks wilt after early promise with US closed	23-09-04	AN
Hopes of rate peak, China turnaround lift stocks	23-09-04	AN
AIM WINNERS & LOSERS: Physiomics brings in COO; Ergomed receives bid	23-09-04	AN
Advanced Medical issues profit warning following royalty issues	23-09-04	AN
Advanced Medical Solutions Group Updates FY23 Guidance	23-09-04	MT
Morgan Stanley Adjusts Price Target on Organogenesis Holdings to $3 From $5, Maintains Equal-Weight Rating	23-08-11	MT
Top Premarket Decliners	23-08-10	MT
Transcript : Organogenesis Holdings Inc., Q2 2023 Earnings Call, Aug 09, 2023	23-08-09
Organogenesis Holdings Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Earnings Flash (ORGO) ORGANOGENESIS HOLDINGS Posts Q2 Revenue $117.3M, vs. Street Est of $115.1M	23-08-09	MT
Organogenesis Holdings Inc. Withdraws Earnings Guidance for the the 2023	23-08-09	CI
Bionomics Appoints Alan Fisher as Board Chair, Tim Cunningham as Finance Chief	23-07-03	MT

Chart Organogenesis Holdings Inc.

Duration

Period

More charts

Company Profile

Organogenesis Holdings Inc. is a regenerative medicine company focused on the development, manufacture and commercialization of solutions for the advanced wound care and surgical and sports medicine markets. It offers a portfolio of bioactive and acellular biomaterials products in advanced wound care and surgical biologics, including orthopedics and spine. Its advanced wound care products include Apligraf for the treatment of venous leg ulcers and diabetic foot ulcers (DFUs); Dermagraft for the treatment of DFUs; PuraPly AM as an antimicrobial barrier and native, cross-linked extracellular matrix scaffold for a variety of wound types; and Affinity, Novachor and NuShield placental allografts to address a variety of wound sizes and types. Sports Medicine products include NuShield as a surgical barrier and PuraForce as a reinforcement matrix in targeted soft tissue repairs; and Affinity, Novachor, PuraPly MZ, PuraPly AM and PuraPly SX for management of open wounds in the surgical setting.

Sector

Biotechnology & Medical Research

Calendar

2024-05-09 - Q1 2024 Earnings Release

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Organogenesis Holdings Inc.

Trading Rating

Investor Rating

ESG Refinitiv

D+

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

2.51 USD

Average target price

4.833 USD

Spread / Average Target

+92.56%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Biotechnology & Medical Research

	1st Jan change	Capi.
ORGANOGENESIS HOLDINGS INC.	-38.63%	312M
IQVIA HOLDINGS INC.	+0.67%	42.19B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+6.55%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-21.66%	18.2B
MEDPACE HOLDINGS, INC.	+29.96%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-1.57%	11.76B
UNITED THERAPEUTICS CORPORATION	+16.03%	10.4B
BIO-TECHNE CORPORATION	-4.80%	9.94B

Other Biotechnology & Medical Research